Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model‐Informed Dose Selection for Pediatric Development

The BCR‐ABL1 inhibitor ponatinib is approved for the treatment of adults with chronic myeloid leukemia or Philadelphia chromosome–positive acute lymphoblastic leukemia, including those with the T315I mutation. We report a population pharmacokinetic model‐based analysis for ponatinib and its applicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanley, Michael J., Diderichsen, Paul M., Narasimhan, Narayana, Srivastava, Shouryadeep, Gupta, Neeraj, Venkatakrishnan, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pharmacometrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300170/
https://www.ncbi.nlm.nih.gov/pubmed/34699069
http://dx.doi.org/10.1002/jcph.1990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300170/
https://www.ncbi.nlm.nih.gov/pubmed/34699069
http://dx.doi.org/10.1002/jcph.1990

Ejemplares similares